- Previous Close
24.98 - Open
25.00 - Bid 25.64 x 100
- Ask 25.97 x 400
- Day's Range
25.00 - 25.83 - 52 Week Range
22.93 - 53.18 - Volume
33,360 - Avg. Volume
1,109,678 - Market Cap (intraday)
1.712B - Beta (5Y Monthly) 1.59
- PE Ratio (TTM)
-- - EPS (TTM)
-2.58 - Earnings Date Nov 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
67.10
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
www.celldex.comRecent News: CLDX
View More
Performance Overview: CLDX
Trailing total returns as of 11/20/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CLDX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CLDX
View MoreValuation Measures
Market Cap
1.66B
Enterprise Value
904.37M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
152.29
Price/Book (mrq)
2.11
Enterprise Value/Revenue
90.65
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-19.73%
Return on Equity (ttm)
-29.84%
Revenue (ttm)
9.98M
Net Income Avi to Common (ttm)
-154.08M
Diluted EPS (ttm)
-2.58
Balance Sheet and Cash Flow
Total Cash (mrq)
756M
Total Debt/Equity (mrq)
0.39%
Levered Free Cash Flow (ttm)
-83.73M
Research Analysis: CLDX
View MoreCompany Insights: CLDX
CLDX does not have Company Insights